期刊
NATURE NANOTECHNOLOGY
卷 17, 期 9, 页码 993-+出版社
NATURE PORTFOLIO
DOI: 10.1038/s41565-022-01177-2
关键词
-
资金
- Directional Institutionalized Scientific Research Platform of Beijing Synchrotron Radiation Facility of CAS
- National Key R&D Program of China [2021YFE0113000, 2021YFA1200900, 2020YFA0710702]
- National Natural Science Foundation of China [32171390, 31971322, 22027810, 11621505, 32088101]
- CAS International Partnership Program [172644KYSB20210011]
- CAS Strategic Priority Research Program [XDB36000000]
- Chinese Academy of Medical Sciences Innovation Fund for Medical Science [CIFMS 2019-I2M-5-018]
- National Natural Science Foundation of Guangdong Province [2022A1515010549, 2021B1212030007]
- Research and Development Project in Key Areas of Guangdong Province [2019B090917011]
- Shenzhen Science and Technology Program [GJHZ20190821155803877, JCYJ20210324120200001]
- Research and Development Project in Key Areas of Guangzhou [202008070007]
- Science and Technology Innovation Project of IHEP [E25459U210]
- CAS President's International Fellowship Initiative [2022VBA0008, 2021PB0060, 2021PM0059]
- Beijing Municipal Health Commission [2021-1G-1191]
- State Key Laboratory of Natural and Biomimetic Drugs, Peking University [K202001]
A biocompatible and antiviral two-dimensional nanomaterial has been reported, which can firmly adsorb the virus and inhibit viral infection through conformational changes induced by interaction with the spike protein. This study proposes CIPS as a promising nanodrug for future anti-SARS-CoV-2 therapy, and also as a decontamination agent and surface-coating material to reduce SARS-CoV-2 infectivity.
While vaccines have curbed the COVID-19 pandemic, effective therapeutic treatments are few, and might be challenged by SARS-CoV-2 variants. A biocompatible, antiviral two-dimensional nanomaterial is now reported that firmly adsorbs the virus by interaction with the spike protein, inducing the conformational changes that lead to inhibition of viral infection in vitro and in animal models. The global emergency caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic can only be solved with effective and widespread preventive and therapeutic strategies, and both are still insufficient. Here, we describe an ultrathin two-dimensional CuInP2S6 (CIPS) nanosheet as a new agent against SARS-CoV-2 infection. CIPS exhibits an extremely high and selective binding capacity (dissociation constant (K-D) < 1 pM) for the receptor binding domain of the spike protein of wild-type SARS-CoV-2 and its variants of concern, including Delta and Omicron, inhibiting virus entry and infection in angiotensin converting enzyme 2 (ACE2)-bearing cells, human airway epithelial organoids and human ACE2-transgenic mice. On association with CIPS, the virus is quickly phagocytosed and eliminated by macrophages, suggesting that CIPS could be successfully used to capture and facilitate virus elimination by the host. Thus, we propose CIPS as a promising nanodrug for future safe and effective anti-SARS-CoV-2 therapy, and as a decontamination agent and surface-coating material to reduce SARS-CoV-2 infectivity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据